Abstract
Nephrogenic systemic fibrosis (NSF) is a recently characterized systemic fibrosing disorder developing in the setting of renal insufficiency. NSF's rapidly progressive nature resulting in disability within weeks of onset makes early diagnosis important. Two reports of NSF after liver transplantation are known of. We present three cases of NSF developing within a few months after liver transplantation and review the current literature. Loss of regulatory control of the circulating fibrocyte, its aberrant recruitment, in a milieu of renal failure and a recent vascular procedure appear important in its development. Known current therapies lack consistent efficacy. Only an improvement in renal function has the greatest likelihood of NSF's resolution. Delayed recognition may pose a significant barrier to functional recovery in the ubiquitously deconditioned liver transplant patient. Early recognition and implementation of aggressive physical therapy appear to have the greatest impact on halting its progression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2212-2217 |
| Number of pages | 6 |
| Journal | American Journal of Transplantation |
| Volume | 6 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Transplantation
- Pharmacology (medical)
Cite this
}
Nephrogenic systemic fibrosis among liver transplant recipients : A single institution experience and topic update. / Maloo, M.; Abt, P.; Kashyap, R.; Younan, D.; Zand, M.; Orloff, M.; Jain, A.; Pentland, A.; Scott, G.; Bozorgzadeh, A.
In: American Journal of Transplantation, Vol. 6, No. 9, 01.09.2006, p. 2212-2217.Research output: Contribution to journal › Article
TY - JOUR
T1 - Nephrogenic systemic fibrosis among liver transplant recipients
T2 - A single institution experience and topic update
AU - Maloo, M.
AU - Abt, P.
AU - Kashyap, R.
AU - Younan, D.
AU - Zand, M.
AU - Orloff, M.
AU - Jain, A.
AU - Pentland, A.
AU - Scott, G.
AU - Bozorgzadeh, A.
PY - 2006/9/1
Y1 - 2006/9/1
N2 - Nephrogenic systemic fibrosis (NSF) is a recently characterized systemic fibrosing disorder developing in the setting of renal insufficiency. NSF's rapidly progressive nature resulting in disability within weeks of onset makes early diagnosis important. Two reports of NSF after liver transplantation are known of. We present three cases of NSF developing within a few months after liver transplantation and review the current literature. Loss of regulatory control of the circulating fibrocyte, its aberrant recruitment, in a milieu of renal failure and a recent vascular procedure appear important in its development. Known current therapies lack consistent efficacy. Only an improvement in renal function has the greatest likelihood of NSF's resolution. Delayed recognition may pose a significant barrier to functional recovery in the ubiquitously deconditioned liver transplant patient. Early recognition and implementation of aggressive physical therapy appear to have the greatest impact on halting its progression.
AB - Nephrogenic systemic fibrosis (NSF) is a recently characterized systemic fibrosing disorder developing in the setting of renal insufficiency. NSF's rapidly progressive nature resulting in disability within weeks of onset makes early diagnosis important. Two reports of NSF after liver transplantation are known of. We present three cases of NSF developing within a few months after liver transplantation and review the current literature. Loss of regulatory control of the circulating fibrocyte, its aberrant recruitment, in a milieu of renal failure and a recent vascular procedure appear important in its development. Known current therapies lack consistent efficacy. Only an improvement in renal function has the greatest likelihood of NSF's resolution. Delayed recognition may pose a significant barrier to functional recovery in the ubiquitously deconditioned liver transplant patient. Early recognition and implementation of aggressive physical therapy appear to have the greatest impact on halting its progression.
UR - http://www.scopus.com/inward/record.url?scp=33746879941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746879941&partnerID=8YFLogxK
U2 - 10.1111/j.1600-6143.2006.01420.x
DO - 10.1111/j.1600-6143.2006.01420.x
M3 - Article
C2 - 16780542
AN - SCOPUS:33746879941
VL - 6
SP - 2212
EP - 2217
JO - American Journal of Transplantation
JF - American Journal of Transplantation
SN - 1600-6135
IS - 9
ER -